New directions in allergic diseases: Mechanism-based anti-inflammatory therapies

Journal of Allergy and Clinical Immunology

Volumn 106, Issue 1 I, 2000, Pages 5-16

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antagonists; Asthma; Atopic dermatitis; Cytokines; Immunotherapy; Rhinitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ALLERGENICITY; ALLERGIC DISEASE; ASTHMA; ATOPIC DERMATITIS; ATOPY; CYTOKINE PRODUCTION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RHINITIS; TH2 CELL;

EID: 0033912081     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.107930     Document Type: Article

References (121)

1. Barnes PJ. New drugs for asthma. Clin Exp Allergy 1996;26:738-45.
2. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999;402:B31-8
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: an update. Am J Respir Crit Care Med 1998;157:S1-53
4. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-8.
5. Mygind N, Dahl R, Nielsen LP, Hilberg O, Bjerke T. Effect of corticosteroids on nasal blockage in rhinitis measured by objective methods. Allergy 1997;52:39-44.
6. Taylor DA, Jensen MW, Kanabar V, Englestatter R, Steinjans VW, Barnes PJ, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999;160:237-43.
7. Barnes PJ. Antiinflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-72.
8. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41.
9. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55.
10. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;50:515-96.
11. 1-receptor-antagonist drugs. N Engl J Med 1994;330:1663-70.
12. van Ganse E, Kaufman L, Derde MP, Yemault JC, Delaunois L. Effcts of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997;10:2216-24.
13. Walsh GM. The anti-inflammatory effects of cetirizine. Clin Exp Allergy 1994;24:81-5.
14. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
15. Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-94.
16. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
17. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:168-70.
18. Pullerits T, Praks L, Skoogh BE, Ani R, Lötvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999;159:1814-8.
19. Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995;152:2076-83.
20. Krishna MT, Chauhan AJ, Little L, Sampson K, Mant TGK, Hawksworth R, et al. Effect of inhaled APC 366 on allergen-induced bronchoconstriction and airway hyperresponsiveness to histamine in atopic subjects [abstract]. Am J Respir Crit Care Med 1998;157:A456.
21. Barnes PJ. Nitric oxide and airway disease. Ann Med 1995;27:389-93.
22. Hay DW, Henry PJ, Goldie RG. Is endothelin-1 a mediator in asthma? Am J Respir Crit Care Med 1996;154:1594-7.
23. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-57.
24. Egan RW, Umland SP, Cuss FM, Chapman RW. Biology of interleukin-5 and its relevance to allergic disease. Allergy 1996;51:71-81.
25. Leckie MJ, ten Brincke A, Lordan J, Khan J, Diamant Z, Walls CM, et al. SB 240563, a humanized anti-IL-5 monoclonal antibody. Initial single dose safety and activity in patients with asthma [abstract]. Am J Respir Crit Care Med 1999;159:A624.
26. Hogan SP, Matthaei KI, Young JM, Koskinen A, Young IG, Foster PS. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998;161:1501-9.
27. Gavett SH, O'Hearn DJ, Karp CL, Patel EA, Schofield BH, Finkelman FD, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol 1997;272:L253-61.
28. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-23.
29. Tony HP, Shen BJ, Reusch P, Sebald W. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994;225:659-65.
30. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Brocker EB, Mohrs M, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998;160:4004-9.
31. Foster PS. STAT6: an intracellular target for the inhibition of allergic disease. Clin Exp Allergy 1999;29:12-6.
32. Losman JA, Chen XP, Hilton D, Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 1999;162:3770-4.
33. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-61.
34. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mosmann TR, Lo D. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999;162:2477-87.
35. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998;17:1-52.
36. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997;99:657-65.
37. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-3.
38. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and non-allergic lung disease: increased expression in asthma. J Allergy Clin Immunol 2000;105:108-15.
39. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 1998;30:4126-7.
40. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
41. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-84.
42. Elsner J, Petering H, Hochstetter R, Kimmig D, Wells TN, Kapp A, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997;27:2892-8.
43. Barnes PJ, Lim S. Inhibitory cytokines in asthma. Mol Med Today 1998;4:452-8.
44. Selig W, Tocker J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea-pigs. Eur J Pharmacol 1992;213:331-6.
45. Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol 1998;102:344-50.
46. Pretolani M, Goldman M. IL-10: a potential therapy for allergic inflammation? Immunol Today 1997;18:277-80.
47. John M, Lim S, Seybold J, Robichaud A, O'Connor B, Barnes PJ, et al. Inhaled corticosteroids increase IL-10 but reduce MIP-1α, GMCSF and IFN-γ release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998;157:256-62.
48. Zuany-Amorim C, Haile S, Leduc D, Dumarey C, Huerre M, Vargaftig BB, et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 1995;95:2644-51.
49. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113:383-9.
50. Seldon PM, Barnes PJ, Giembycz MA. Interleukin-10 does not mediate the inhibitory effect of PDE4 inhibitors and other cAMP-elevating drugs on lipopolysacchariude-induced tumor necrosis factor-a generation from human peripheral blood monocytes. Cell Biochem Biophys 1998;28:179-201.
51. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
52. Lack G, Bradley KL, Hamelmann E, Renz H, Loader J, Leung DY, et al. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice. J Immunol 1996;157:1432-9.
53. Boguniewicz M, Martin RJ, Martin D, Gibson U, Celniker A. The effects of nebulized recombinant interferon-in asthmatic airways. J Allergy Clin Immunol 1995;95:133-5.
54. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999;103:468-75.
55. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-65.
56. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
57. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-36.
58. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-production. Blood 1997;90:2541-8.
59. Bryan S, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Am J Respir Crit Care Med. In press 2000.
60. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997;158:4137-44.
61. Torphy TJ. Phosphodiesterase isoenzymes. Am J Respir Crit Care Med 1998;157:351-70.
62. Chan SC, Hanifin JM. Differential inhibitor effects on phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:44-51.
63. Harbison PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CD840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997;10:1008-14.
64. Muller T, Engels P, Fozard J. Subtypes of the type 4 cAMP phosphodiesterase: structure, regulation and selective inhibition. Trends Pharmacol Sci 1996;17:294-8.
65. 2-adrenoreceptor desensitization. J Biol Chem 1998;273:20575-88.
66. Li L, Yee C, Beavo JA. CD3-and CD28-dependent induction of PDE7 required for T cell activation. Science 1999;283:848-51.
67. Barnes PJ, Karin M. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
68. Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998;12:221-34.
69. Pahl HL, Krauss B, Schultze-Osthoff K, Decker T, Traenckner M, Myers C, et al. The immunosuppress ive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB. J Exp Med 1996;183:1829-40.
70. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-47.
71. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann NY Acad Sci 1998;851:139-46.
72. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ. p38alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol 1999;162:7110-9.
73. Kankaanranta H, Giembycz MA, Barnes PJ, Lindsay DA. SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999;290:621-8.
74. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 1996;13:2595-605.
75. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 1996;183:1407-14.
76. Amoui M, Draber P, Draberova L. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both FcεRI-and Thy-1-mediated activation of rat basophilic leukemia cells. Eur J Immunol 1997;27:1881-6.
77. Lynch OT, Giembycz MA, Barnes PJ, Hellewell PG, Lindsay MA. 'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils. Br J Pharmacol 1999;128:1149-58.
78. 4-induced eosinophil activation. Blood. In press 2000.
79. Pilewski JM, Albelda SM. Cell adhesion molecules in asthma: homing activation and airway remodelling. Am J Respir Cell Mol Biol 1995;12:1-3.
80. Weg VB, Williams TJ, Lobb RR, Noorshargh S. A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med 1993;177:561-6.
81. Sun J, Elwood W, Haczku A, Barnes PJ, Hellewell PG, Chung KF. Contribution of intracellular adhesion molecule-1 in allergen-induced airway hyperresponsive ness and inflammation in sensitised Brown-Norway rats. Int Arch Allergy Immunol 1994;104:291-5.
82. Yuan Q, Strauch KL, Lobb RR, Hemler ME. Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function. Biochem J 1996;318:591-6.
83. Lin Kc, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem 1999;42:920-34.
84. Abraham WM, Ahmed A, Sabater JR, Lauredo IT, Botvinnikova Y, Bjercke RJ, et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 1999;159:1205-14.
85. Kim MK, Brandley BK, Anderson MB, Bochner BS. Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am J Respir Cell Mol Biol 1998;19:836-41.
86. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
87. Nizankowska E, Soja J, Pinis G, Bochenek G, Stadek K, Domgala B, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995;8:1091-9.
88. Morley J. Cyclosporin A in asthma therapy: a pharmacological rationale. J Autoimmun 1992;5(Suppl A):265-9.
89. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998;102:555-7.
90. Thompson AG, Starzl TC. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 1993;136:71-98.
91. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised dose-ranging placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352:1109-13.
92. Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Hamelmann E, Gelfand EW. CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J Immunol 1999;162:4207-11.
93. Zhang Z, Zimonjic DB, Popescu NC, Wang N, Gerhard DS, Stone EM, et al. Human uteroglobin gene: structure, subchromosomal localization, and polymorphism. DNA Cell Biol 1997;16:73-83.
94. Caramori G, Lim S, Ciaccia A, Fabbri LM, Barnes PJ, Adcock IM. GATA transcription factor expression in T cells, monocytes and bronchial biopsies of normal and asthmatic subjects [abstract]. Am J Respir Crit Care Med 1999;157:A908.
95. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 1996;183:901-13.
96. Heinke S, Szucs G, Norris A, Droogmans G, Nilius B. Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br J Pharmacol 1995;115:1393-8.
97. Wang L, Correia I, Basu S, Theoharides TC. Ca2+ and phorbol ester effect on the mast cell phosphoprotein induced by cromolyn. Eur J Pharmacol 1999;371:241-9.
98. Bianco S, Pieroni MG, Refini RM, Robuschi M, Vaghi A, Sestini P. Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J 1993;6:130-4.
99. Barnes PJ. Diuretics and asthma. Thorax 1993;48:195-7.
100. Yates DH, O'Connor BJ, Yilmaz G, Aikman S, Chen-Worsdell M, Barnes PJ, et al. Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am J Respir Crit Care Med 1995;152:892-6.
101. Haczku A, Takeda K, Redai I, Hamelmann E, Cieslewicz G, Joetham A, et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1999;159:1638-43.
102. Van Oosterhout AJ, Hofstra CL, Shields R, Chan B, van Ark I, Jardieu PM, et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997;17:386-92.
103. van Neerven RJ, Van de Pol MM, van der Zee JS, Stiekema FE, De Boer M, Kapsenberg ML. Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin Exp Allergy 1998;28:808-16.
104. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
105. Milgrom H, Fick RB Jr, Su JQ, Reimann J, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-73.
106. Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med 1999;341:2006-8.
107. Dasic G, Juillard P, Graber P, Herren S, Angell T, Knowles R, et al. Critical role of CD23 in allergen-induced bronchoconstriction in a murine model of allergic asthma. Eur J Immunol 1999;29:2957-67.
108. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-75.
109. Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2:540-4.
110. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5:387-91.
111. Yssel H, Fasler S, Lamb J, de Vries JE. Induction of non-responsiveness in human allergen specific type 2 helper cells. Curr Opin Immunol 1994;6:847-52.
112. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
113. Haselden BM, Barry Kay A, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885-94.
114. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
115. Strannegard IL, Larsson LO, Wennergren G, Strannegard O. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy 1998;53:249-54.
116. Herz U, Gerhold K, Gruber C, Braun A, Wahn U, Renz H, et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol 1998;102:867-74.
117. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998;93:307-13.
118. Wheeler MA, Smith SD, Garcia Cardena G, Nathan CF, Weiss RM, Sessa WC. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 1997;99:110-6.
119. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:6284-93.
120. Xing Z, Ohkawara Y, Jordana M, Grahern FL, Gauldie J. Transfer of granulecyte-macrophage colony-stimulating factor gene to rat induces eosinophilia, monocytosis and fibrotic lesions. J Clin Invest 1996;97:1102-10.
121. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997;385:721-5.